NCT01778413

Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 61 (actual)
• Sponsor: Anna Cruceta · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main objective is to determine the feasibility of maintaining virologic suppression on standard plasma viral load by dose reduction of ATRIPLA ®.

Detailed description

The main objective of this study is to determine the feasibility of maintaining virologic suppression on standard plasma viral load (limit of detection 37 copies / mL) of a dose reduction strategy of ATRIPLA ® once a day to three tablets per week in patients infected with HIV-1 with sustained suppression of plasma viral load standard for more than two years.

Conditions

• HIV

Interventions

Type	Name	Description
DRUG	ATRIPLA

Timeline

• Start date: 2013-06-03
• Primary completion: 2014-11-14
• Completion: 2015-07-21
• First posted: 2013-01-29
• Last updated: 2025-07-18
• Results posted: 2025-07-18

Locations

1 site across 1 country: Spain